Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug may offer longer-lasting bleed control for rare platelet disorder

NCT ID NCT06234813

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This lab study tested whether concizumab, a drug that blocks a natural clotting inhibitor, can improve blood clotting in people with Glanzmann thrombasthenia (GT), a rare genetic bleeding disorder. Blood samples from 20 adults with GT and healthy donors were mixed with concizumab and measured for clot formation. The goal is to see if concizumab could replace current treatments that require frequent injections, offering a longer-lasting (about 3 days) and easier-to-use option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Apr 2023

Finished

Jul 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Glanzmann Thrombasthenia Group: * Patient ≥18 years old * Patient with a clear diagnosis of Glanzmann Thrombasthenia (GT), whatever the subtype of disease * Affiliated person or beneficiary of a social security scheme. * Free, informed and written consent signed by the participant, and the investigator (at the latest on the day of inclusion and before any examination required by the research) Control Group: * Healthy donor ≥ 18 years old * Healthy donor, without haemorrhagic ant thrombotic medical history * Person should not work in the investigator's department. * Affiliated person or beneficiary of a social security scheme * Free, informed and written consent signed by the participant, and the investigator (at the latest on the day of inclusion and before any examination required by the research) Exclusion Criteria: For both patient groups: * Patient who has taken aspirin or a nonsteroidal anti-inflammatory medication within the previous 10 days * Patient who has received a platelet transfusion or recombinant activated factor VII hemostatic treatment within the previous 7 days * Patient who participated in another interventional study involving a drug within 30 days of entering this protocol * Psychiatric, social or behavioral condition judged to be non-compatible with the respect of the protocol * Adult protected by the law

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glanzmann thrombasthenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Glanzmann thrombasthenia Glanzmann thrombasthenia 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glanzmann thrombasthenia

Contacts and locations

Locations

  • CHU Bordeaux - Laboratoire Hématologie

    Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.